Viralytics – oncolytic immunotherapies

Viralytics is a biotech company focusing on the development of oncolytic immunotherapies, using the specific property of certain viruses to preferentially infect and kill cancer cells. Viralytics’ lead product candidate is CAVATAK, a proprietary formulation of the common Coxsackievirus Type A21 (CVA21), evaluated in Phase 1 and 2 clinical trials.

Viralytics – oncolytic immunotherapies

Viralytics

Continue reading